Artemisinin Combination Therapy Market

1
Artemisinin Combination Therapy Market Size,
Share Trends Analysis Report and Segment
Forecast, 2025 Grand View Research, Inc
The artemisinin combination therapy market size
was valued at USD 363.8 million in 2017. It is
projected to expand at a CAGR of 8.5 during the
forecast period.
The global Artemisinin Combination Therapy (ACT)
Market size is expected to reach USD 697.9
million by 2025, according to a new report by
Grand View Research, Inc., progressing at a CAGR
of 8.5 during the forecast period. Rising
adoption rate of ACTs coupled with growing
government initiatives to combat malaria epidemic
is anticipated to stoke the growth of the
market. Furthermore, expanding pipeline and new
product approvals are driving the
market. Currently, 6 ACTs are recommended by WHO
for the treatment of uncomplicated malaria, which
are Artemether-Lumefantrine (AL),
artesunate-amodiaquine, Artesunate-Mefloquine
(AS-AQ), Dihydroartemisinin- Piperaquine
(DHA-PPQ), Artesunate-Sulfadoxine-Pyrimethamine
(AS-SP), and Pyronaridine-Artesunate (PR-AS).
Some of the benefits provided by ACTs are high
efficacy and reduced likelihood of developing
resistance. Over the years, access to
artemisinin combination therapy has expanded
considerably. In 2016, ACTs were used as
first-line treatment in almost 80
countries. Increasing R D initiatives by
pharma-emerging countries such as India and China
are revving up the adoption rate of ACTs. Rising
demand from malaria endemic countries such as
Kenya, Uganda, Nigeria, and Congo is poised to
augment the market. Pipeline for new antimalarial
drugs is widening and some of them have been
introduced recently. These are some of the
factors that are propelling the ACT market. WHO
states the necessity for treating uncomplicated
malaria, the most serious form of the disease,
with ACTs as they are the best treatment
available. ACTs are recommended over other
treatments including Sulfadoxine-
2

• pyrimethamine, chloroquine, and artemisinin
  monotherapies, because parasites have developed
  resistance to these medicines.
• Malaria is one of the most distressing diseases
  across the globe with more than 200 million new
  cases reported each year. According to Medicines
  Malaria Venture (MMV), a total of 445,000 deaths
  were caused by malaria worldwide in 2016.
  Malaria epidemic is continuing to increase
  globally and climate change is projected to fuel
  the trend.
• To request a sample copy or view summary of this
  report, click the link below
• https//www.grandviewresearch.com/industry-analysi
  s/artemisinin-combination-therapy-act-market
• Further key findings from the report suggest
• AL was the largest segment in 2017 due to the
  fact that it was the first ACT to be marketed and
  prequalified by WHO for its efficacy, safety,
  and quality. It is available in more than 60
  countries and is the only ACT approved by U.S.
  FDA
• MEA held the largest share in the market for ACTs
  due to growing initiatives by government and non-
  government organizations to raise awareness
• Asia Pacific also held a prominent position in
  the market owing to factors such as large
  production base of artemisinin herbs coupled
  with rising access to ACT in this region
• Major players operating in the market are
  Novartis, Sanofi, Cipla, Ajanta Pharma, Ipca
  Laboratories, Guilin Pharmaceuticals, and KPC
  Pharmaceuticals
• Key players are adopting different strategies to
  increase their market share such as increasing
  geographic presence, R D, new product
  development, and indication extension.
• Grand View Research has segmented the global
  artemisinin combination therapy market on the
  basis of type and region

3

• Asia Pacific
• China
• India
• Pakistan
• Indonesia
• Vietnam
• Latin America
• Brazil
• Colombia
• Middle East Africa

4

• Table of Content of Artemisinin Combination
  Therapy Market
• Chapter 1 Research Methodology Scope
• Information Procurement
• Purchased database
• GVRs internal database
• Research Methodology
• Geographic Scope Assumptions
• Region-wise Market Calculation
• Region-wise market Base estimates
• Global market CAGR calculation
• Region-based Segment Share Calculation
• List of Secondary Sources
• Chapter 2 Executive Summary
• 2.1 Market Snapshot
• Chapter 3 Market Variables, Trends Scope
• Market Segmentation Scope
• Market Driver Analysis
• Rising Demand for Artemisinin Combination Therapy
  (ACT)

5

• Dihydroartemisinin-Piperaquine
• Dihydroartemisinin-Piperaquine Market estimates
  and forecast, 2014 - 2025 (USD Million)
• Artesunate-Mefloquine
• Artesunate-Mefloquine Market estimates and
  forecast, 2014 - 2025 (USD Million)
• Artesunate-Sulfadoxine-Pyrimethamine
• Artesunate-Sulfadoxine-Pyrimethamine Market
  estimates and forecast, 2014 - 2025 (USD Million)
• Pyronaridine-Artesunate
• Pyronaridine-Artesunate Market estimates and
  forecast, 2014 - 2025 (USD Million)
• Chapter 5 Artemisinin Combination Therapy (ACT)
  Market Regional Outlook
• 5.1 ACT market share by region, 2017 2025 (USD
  Million)
• Asia Pacific
• China
• India
• Pakistan
• Indonesia
• Vietnam
• Latin America
• Brazil
• Colombia

6

• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
• Guilin Pharmaceutical Co., Ltd
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
• Sanofi
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
• Desano Inc.
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives

7

• Financial performance
• Product benchmarking
• Strategic initiatives
• DENK PHARMA GmbH Co.KG
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
• Hovid-Integrated Global Pharmaceutical Partner
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
• Ipca Laboratories Ltd.
• Company overview
• Financial performance
• Product benchmarking
• Strategic initiatives
• Shelys Africa Pharmaceuticals Ltd.

8
About Us Grand View Research, Inc. is a U.S.
based market research and consulting company,
registered in the State of California and
headquartered in San Francisco. The company
provides syndicated research reports, customized
research reports, and consulting services. To
help clients make informed business decisions,
the company offers market intelligence studies
ensuring relevant and fact-based research across
a range of industries including technology,
chemicals, materials, healthcare and
energy. Contact Sherry James Corporate Sales
Specialist, USA Grand View Research, Inc Phone
1-415- 349-0058 Toll Free 1-888- 202-9519 Email
sales_at_grandviewresearch.com For More Information
https//www.grandviewresearch.com Blog
https//healthcareforecastreport.blogspot.com/